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Resumo
A modelação matemática é uma ferramenta poderosa que permite a
representação virtual de fenómenos físicos e biológicos complexos e con-
tribui para a compreensão do papel de cada sub fenómeno e da influência
dos parâmetros do modelo no seu comportamento global. Para além
disso, pode ser usada na construção de novos protocolos médicos, novos
dispositivos para aplicação de fármacos e no planeamento de novas ex-
periências e tratamentos.
Este trabalho é dedicado ao estudo da libertação controlada de fárma-
cos a partir de dispositivos iontoforéticos. O transporte do fármaco e a
sua absorção são favorecidos por campos elétricos. O fenómeno de liber-
tação de fármaco é descrito por equações de convecção-difusão acopladas
em que o coeficiente convectivo é definido pela equação de Nernst-Planck.
Iniciamos este trabalho com um modelo simplificado em que admiti-
mos que o fármaco está em contacto com o tecido alvo. Neste caso,
é estabelecida uma fórmula explícita para a concentração obtida uti-
lizando a análise de Fourier. Na parte central do trabalho, o compor-
tamento qualitativo do problema acoplado é analisado de um ponto de
vista analítico e numérico. São estabelecidas estimativas de energia que
nos permitem caracterizar a massa de fármaco absorvida. No ponto de
vista numérico, é proposto um método de diferenças finitas e são estu-
dadas as suas propriedades de estabilidade e convergência. Resultados
numéricos que ilustram o comportamento qualitativo do sistema com-
plexo são apresentados.
Palavras Chave: Libertação de fármacos, Iontoforese, Equação de Nernst-Plack,
Equações de convecção-difusão acopladas
Abstract
Mathematical modelling is a powerful tool that allows a virtual repre-
sentation of complex physical and biological phenomena and contributes
to the understanding of the role of each phenomenon and the influence of
the parameters of the model in its global behavior. Furthermore, it can
be used to help the design of new protocols, new drug delivery devices
and plan new experiments and treatments.
This work is devoted to the study of the controlled drug delivery
from iontophoretic systems. The drug is entrapped in a reservoir which
is in contact with a target tissue. The drug transport and its absorption
are enhanced by an applied electric field. The drug release is described
by coupled convection-diffusion equations, being the convective velocities
given by the Nernst-Planck equation.
i
We start by considering a simplified model where the drug is in contact
with the target tissue. In this case, an explicit expression for the drug
concentration is obtained using Fourier analysis. In the main part of
this work, the qualitative behavior of the coupled problems is analysed
from theoretical and numerical points of view. Energy estimates are
established that allow the characterization of the absorbed drug mass.
From a numerical point of view, a finite difference method is proposed
and its stability and convergence are established. Numerical results that
illustrate the qualitative behavior of the drug concentration are included.
Keywords: Drug delivery, Iontophoresis, Nernst-Planck equation, Coupled convection-
diffusion equations
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Chapter 1
Introduction
Medical treatments using preparations for the skin, such as ointments and salves,
are among the first to be recorded in medicine history. The transdermal route for
drug delivery has since been one of the most used even today, mostly because of it's
easy access and also for being potentially non-invasive. However, skin is foremost an
important barrier in our defense system and, as such, constitutes an hindrance to
most drugs by impeding the permeation and preventing them to reach the circulatory
system in sufficient quantities.
To tackle this obstacle, several methodologies to increase skin permeation have
been developed ([7]). Without being exhaustive, we mention: the use of chemical
agents, even though an ideal chemical for penetration enhancement is hard to find;
the sonophoresis, which uses ultrasound waves to stimulate micro-vibrations within
the skin epidermis and creates a convective transport of the permeant across the
skin; microneedles have also been used to bypass the stratum corneum (SC) through
various techniques, such as coating the microneedles with the drug, or even using
dissolvable microneedles with biodegradable polymeric materials ([15]) and letting
the drug diffuse through the skin into the circulatory, after inserting them through
the SC; the use of nanocarriers, the most used for transdermal drug delivery are lipo-
somes, dendrimers, nanoparticles and nanoemulsions ([12]); and finally, a technique
called iontophoresis, which consists in an application of a low electrical potential
gradient over extended periods of time via an electrical circuit constituted by two
oppositely charged drug reservoirs placed on the skin surface.
The last method, which is the object of this work, became popular at the be-
ginning of the 20th century through the work of LeDuc (1900). The electric field
created enhances the flux or rate of absorption of ionic solutes into the skin. By al-
ternately applying and terminating the current, one can have a greater control over
the quantities of drug administered. A similar method called electroporation consists
of applying a higher electrical potential gradient over shorter periods of time, which
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breaks the cell membrane down and forms nano-scale defects or pores in the mem-
brane ([1],[2], [3], [20]). Iontophoresis can be used in conjunction with electroporation
and the previously refered methods. It should be remarked that iontophoresis is also
applied to treat pancreatic cancer, using chemotherapy to shrink the tumor or to
stop it's growth ([4]), therefore making some patients eligible to surgery which oth-
erwise would not be. Ocular iontophoresis has been investigated to treatments such
as dry eye syndrome. Dentistry has also recurred to iontophoretic uses in treating
hypersensitive dentin, oral ulcers and delivering local anesthetics ([13]). Another im-
portant application regards the reverse iontophoresis, an alternative for non-invasive
clinical and therapeutic drug monitoring ([7],[5]).
Some of the iontophoretic systems use stimuli-responsive polymers, where the
drug is entrapped, that are able to respond to the modification of external envi-
ronment like electric fields, pH, and temperature. Electric fields are an attractive
stimulus because they can be precisely controlled, and the drug delivery responses
can be predicted.
Each of the above applications involve complex phenomena. For instance, in
transdermal drug delivery enhanced by an electric field, the drug leaves the poly-
meric matrix, enters the stratum corneum and is transported through the skin to
reach the circulatory system. In both media the transport occurs by passive diffu-
sion, electromigration-migration of ions due to the electric field, and electroosmosis-
transport due the solvent movement ([10], [17], [19]).
Let us consider a coupled system: a reservoir containing a charged drug which
is in contact with a target tissue. In iontophoresis procedure, a small electric field
is applied to the coupled system. If the drug molecules are positively charged, then
the anode is in contact with the reservoir and the cathode is in an opposite position.
The generated electric field induces a convective field in the system that depends
on the drug molecules' valence, intensity of the electric field, temperature, electric
conductivity of both media and drug diffusion in the medium ([10],[11]).
Mathematical modelling is a powerful tool that allows a virtual representation of
the physical and biological phenomena involved and contributes to the understanding
of the role of each phenomenon, the influence of the parameters of the model in its
global behavior and to justify experimental data. Furthermore, it can be used to help
the design of new protocols, new drug delivery devices and plan new experiments
and treatments.
2
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The main objective of this work is the mathematical modelling of the drug re-
leased from a polymeric matrix and its entrance in a target tissue when the ion-
tophoresis procedure is used. In this case, the drug delivery from a polymeric device
is enhanced by an electric field of low intensity, which is applied during long pe-
riods of time, and its entrance in a target tissue is also enhanced by the electric
field. The mathematical model is characterized by partial differential equations that
describe the transport through the media-polymeric matrix and target tissue, and
the evolution of the electric field which is described by the Laplace equation in both
media. The electric potential induces a convective field that enhances the drug
transport. Then, the time-space evolution of the drug in both media is described
by convection-diffusion equations and additional conditions: initial, boundary and
interface conditions ([11]).
This work is organized as follows. In Chapter 2 we consider the case in which the
drug is in direct contact with the target tissue, with an electrode inside the target. An
analytical study is presented regarding existence and uniqueness of a solution of the
convection-diffusion equation, and the obtained solution is illustrated. In Chapter
3 the more complex case of a drug encapsulated in a reservoir is studied. Solving
the coupled problem for the electric field, the convective field is explicitly given and
the electric field and drug equations are replaced by coupled convection-diffusion
equations. Energy estimates are obtained and used to guarantee the uniqueness and
stability of the coupled model, as well as to compute lower bounds for the absorbed
drug. As we are not able to obtain an explicit expression for the drug concentration,
we introduce an explicit Euler method, that allow us to compute an approximation
for the solution. The stability and convergence of the proposed numerical method
are presented. Some numerical results obtained with Matlab are also included. We
observe that part of these studies were published in [8]. In Chapter 4 we present
some conclusions.
3
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Drug in contact with the target
tissue
2.1. Introduction
The main objective of this Chapter is the study of the situation when the drug is
constantly being delivered directly to the target tissue. To enhance the drug diffusion,
we assume that an electric field is applied. In this case the drug mass flux J has
two main contributes: the Fick's mass flux and a convective mass flux induced by
the electric field. Here we shall neglect the osmotic mass flux and assume that the
target tissue is an isotropic medium. This last assumption allow the replacement of
the 3D model by a 1D model. The iontophoretic device is considered with the anode
and cathode placed in the intended direction of the drug and opposite to each other,
with one being implanted in the intended target. This can be the case as in the
administration of cytotoxic therapies ([4]). This Chapter is organized as follows: in
Section 2.2 we present the evolution of the drug concentration. The construction of
the solution of the initial value problem introduced in the previous Section is made
using the method of separation of variables in Section 2.3. This construction allows
us to illustrate the drug concentration behavior in Section 2.4 and the response to
the changes of some parameters.
2.2. Evolution of the drug concentration
Let c(x, t) (g/m3) represent the drug concentration in x ∈ [0, `] at time t ≥ 0. In
x = 0 we have the point of contact between the drug and the tissue and in x = ` the
point of desired absorption as in figure 2.1. Consider cext to be the concentration
of drug molecules at x = 0. At the initial time t = 0 we do not have any drug in
the tissue and we assume that the drug is completely absorbed at x = `. These
assumptions can be summarized by
c(0, t) = cext , t ≥ 0 , c(`, t) = 0 , t ≥ 0 , c(x, 0) = 0 , x ∈ (0, `) . (2.1)
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Anode/
Cathode
Cathode/
AnodeTissue
x = 0 x = `
Figure 2.1: Considered model.
The drug mass flux (gm−2 s−1) is given by the Nernst-Planck equation
J = −D∇c− vc , (2.2)
where D (m2 s−1) is the diffusion coefficient and v the convection velocity induced
by the applied electric field
v =
zDF
RT
∇Φ (2.3)
where z denotes the valence of the drug molecules, F the Faraday constant (9.6485×
104 Coulomb/mol), T the temperature (K) in the tissue, R the gas constant (8.31446
JK−1mol−1) and Φ (V) the electric potential.
The mass conservation law dictates
∂c
∂t
+∇ · J = 0, (2.4)
and from (2.2) we obtain
∂c
∂t
= ∇ · (D∇c) +∇ · (vc) . (2.5)
Next we shall compute the gradient of the potential. We assume that during the
period of application, Φ does not change over time. Then
∆Φ = 0 , in (0, `) . (2.6)
Since the applied potential is known,
Φ(0) = Φ0 Φ(`) = Φ1 , (2.7)
we obtain
v =
zDF
RT
Φ1 − Φ0
`
. (2.8)
Regarding the ionic valance z and the potential difference ∇Φ, we make the
following observation. If the ionic specie has a positive electric charge, one needs
to generate a potential difference by placing the anode in the left-hand side of the
6
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x = 0
+ + -
x = `
Figure 2.2: Scheme for a positively charged drug.
x = 0
- - +
x = `
Figure 2.3: Scheme for a negatively charged drug.
target tissue and the cathode in the opposite side. In figure 2.3 we illustrate the
converse situation for a negative ionic valence.
Finally we conclude from (2.5) and (2.1), and considering the 1D simplification,
that the evolution of the drug concentration is described by the following initial and
boundary value problem
∂c
∂t
= D
∂2c
∂x2
+
∂
∂x
(vc) in (0, `)× R+
c(x, 0) = 0, x ∈ (0, `)
c(0, t) = cext , c(`, t) = 0, t ∈ R+0
. (2.9)
2.3. Existence and uniqueness results
In what follows we will study the existence and uniqueness of the solution of the
IBVP (2.9). We start our analysis by assuming that solutions for this problem exist
and we will prove the uniqueness of such a solution.
Theorem 1. The IBVP (2.9) has at the most one solution c(t) ∈ H2(Ω) and ∂c
∂t
(t) ∈
L2(Ω).
We shall use the following notations: for t ∈ R+0 , by c(t) we denote the function
c(t) : [0, `]→ R
x 7→ c(x, t).
Let L2(0, `) be the usual space of square integrable functions with the usual inner
product ( , ) and norm ‖ . ‖. By H1(0, `), H10(0, `) we represent the usual Sobolev
spaces.
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Suppose that c satisfies the Dirichlet homogenous boundary conditions and the
initial condition holds as stated in (2.9). Then, from (2.5) we obtain
(c′(t), w) + (D∇c(t),∇w) + (∇vc,∇w) = 0 , ∀w ∈ H2(0, `) (2.10)
If (2.9) has two solutions c1 and c2, then c = c1−c2 satisfies (2.10). Consequently,
taking w = c we get
1
2
d
dt
||c(t)||2 +D||∇c(t)||2 + (vc(t),∇c(t)) = 0
and since
(vc(t),∇c(t)) ≤ v
2
4ε2
||c(t)||2 + ε2||∇c(t)||2
∀ε ∈ R\ {0}, we obtain
1
2
d
dt
||c(t)||2 + (D − ε2)||∇c(t)||2 − v
2
4ε2
||c(t)||2 ≤ 0 . (2.11)
Choosing ε2 = D we establish
1
2
d
dt
||c(t)||2 − v
2
4D
||c(t)||2 ≤ 0 , ∀t > 0 . (2.12)
Gronwall's lemma allow us to obtain the following estimate
||c(t)||2 ≤ e v
2
4D
t||c(0)||2 , ∀t ≥ 0 . (2.13)
Inequality 2.13 leads to the uniqueness of the solution of the IBVP (2.9) and
its stability. In fact, if c1 and c2 are both solutions of (2.9) with different initial
conditions, then
||c1(t)− c2(t)||2 ≤ e v
2
4D
t||c1(0)− c2(0)||2 , ∀t > 0 . (2.14)
Consequently, we conclude that we have stability, but only in bounded time intervals.
Let us now show that a solution of the problem exists.
Theorem 2. The function c(x, t) = `−x` cext + e
αx+βt
∑+∞
n=0 an(t)sin(
npix
` ), (x, t) ∈
[0, `]× R+0 with
• an(t) = Bn e
−βt − e−d(npi` )2t
d(npi` )
2 − β + e
−d(npi
`
)2tan(0) ,
• an(0) = −2cext
`
e−α``(eα`npi(α`(−2 + α`) + n2pi2)− 2α`npi cos(npi)
((α`)2 + (npi)2)2
• Bn = 2vcext
`2
(
npi`(1− eα` cos(npi)
(npi)2 + (α`)2
)
,
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• α = − v2D and β = − v
2
4D ,
satisfies the convection-diffusion equation (2.9) and the initial conditions in the sense
that the boundary conditions hold.
Proof. We start by reducing the boundary condition to a homogenous boundary
condition considering w = c− w0, where
w0(x) =
`− x
`
cext .
As we have
∂w
∂t
=
∂c
∂t
− ∂w0
∂t
=
∂c
∂t
= D
∂2c
∂x2
+
∂
∂x
(vc)
= D
∂2w
∂x2
+
∂
∂x
(vw) +
v
`
cext ,
we conclude for w
∂w
∂t = D
∂2w
∂x2
+ ∂∂x(vw) +
v
` cext in (0, `)× R+
w(x, 0) = − `−x` cext , x ∈ (0, `)
w(0, t) = 0 , w(`, t) = 0 , t ∈ R+
. (2.15)
To remove the term ∂∂x(vw) we introduce the new variable w(x, t) = e
αx+βtg(x, t),
where α and β will be fixed later. Then we have
∂w
∂t
(x, t) = βeαx+βtg(x, t) + eαx+βt
∂g
∂t
(x, t)
∂w
∂x
(x, t) = αeαx+βtg(x, t) + eαx+βt
∂2w
∂x2
(x, t) = α2eαx+βtg(x, t) + 2αeαx+βt
∂g
∂x
(x, t) + eαx+βt
∂2g
∂x2
(x, t) .
From equations (2.15) and dividing by eαx+βt on both sides we obtain
∂g
∂t
(x, t) = g(x, t)
(
Dα2 + vα− β)+ ∂g
∂x
(x, t)(2αD+v)+
∂2g
∂x2
(x, t)D+
v
`
cexte
−αx−βt .
Fixing α = − v2D and β = − v
2
4D we get for g the following IBVP
∂g
∂t (x, t) = D
∂2g
∂x2
(x, t) + v` cexte
−αx−βt , (x, t) ∈ (0, `)× R+
g(x, 0) = − `−x` cexte−αx , x ∈ (0, `)
g(0, t) = 0 , g(`, t) = 0 , t ∈ R+
. (2.16)
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We prescribe for the solution of (2.16) the following form
g(x, t) =
+∞∑
n=1
an(t) sin
(npix
`
)
. (2.17)
Let f(x, t) = v` cexte
−αx−βt. Then f(x, t) = e−βtf(x) where
f(x) =
+∞∑
n=1
Bn sin
(npix
`
)
and Bn, the Fourier coefficients of f(x), are given by
Bn =
2vcext
`
(
npi(1− e−α` cos(npi)
(npi)2 + (α`)2
)
.
We establish in what follows, a differential equation for the Fourier coefficients
an(t). We have
∂g
∂t
(x, t) =
+∞∑
n=1
a′n(t) sin
(npix
`
)
.
From the differential equation for g we deduce
+∞∑
n=1
a′n(t) sin
(npix
`
)
= −D
+∞∑
n=1
an(t)
(npix
`
)2
sin
(npix
`
)
+ e−βt
+∞∑
n=1
Bn sin
(npix
`
)
.
Therefore, we are led to the following differential equation
a′n(t) = −D
(npix
`
)2
an(t) + e
−βtBn (2.18)
which is complemented by the Fourier coefficients of g(x, 0) given by
an(0) = −2cext
`
e−α``(eα`npi(α`(−2 + α`) + n2pi2) + 2αn`pi cos(npi))
((α`)2 + (npi)2)2
. (2.19)
Solving the initial value problem (2.18), (2.19) we obtain
an(t) = Bn
e−βt − e−d(npi` )2t
d(npi` )
2 − β + e
−d(npi
`
)2tan(0) .
Since w = c− w0, then
c(x, t) = w(x, t) + w0(x) = e
αx+βtg(x, t) + w0(x) ,
that is,
c(x, t) =
`− x
`
cext + e
αx+βt
+∞∑
n=1
an(t) sin
(npix
`
)
, x ∈ [0, `] , t ≥ 0 . (2.20)
It remains to check if c is indeed a solution of the IBVP. We prove in what follows
that g(x, t) exists for x ∈ [0, `], t ≥ 0, that is, the series in the right-hand side of
(2.20) is uniformly convergent in [0, `]× [γ, T ] for γ > 0, γ < T and a fixed T .
10
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We remark that for x ∈ [0, `]× [γ, T ] we have∣∣∣an(t) sin(npix
`
)∣∣∣ ≤ const [( n
n2 + α′
)(
1
n2 − β′
)
+ e
−d
(
n2pi2
`
)(
n3 + n
(αˆ+ n2)2
)]
for convenient constants α′, αˆ, β′ and for n ≥ n0 such that n2 − β′ > 0. In the last
inequality and in what follows we denote const also a convenient constant.
As
∑+∞
n=n0
n
(n2+α′)(n2−β′) and
∑+∞
n=n0
e
−d
(
n2pi2
`
)
n3+n
(αˆ+n2)2
are convergent series, we
conclude that
∑+∞
n=1 an(t) sin
(
npix
`
)
is uniformly convergent in [0, `] × [γ, T ] and so,
it defines a continuous function in [0, `] × [γ, T ]. Finally, we conclude that g exists
and is continuous in [0, `]× R+.
Following the previous procedure for
+∞∑
n=1
a(i)n (t)
(
d
dx
)j
sin
(npix
`
)
, x ∈ (0, ` , t ∈ [γ, T ] ,
it can be shown that
∂i+jg
∂xi∂tj
exists and is continuous in (0, `)× R+.
By the construction of the ordinary differential problem for an(t), it is easy to
conclude that g satisfies the differential equation of the IBVP (2.16).
We will now prove that g satisfies the initial condition in (2.16) in the sense that
(2.16) holds. Let Ψ ∈ L2(0, `). We have
lim
t→0+
(g(t),Ψ) = lim
t→0+
+∞∑
n=1
an(t)
∫ `
0
Ψ(x) sin
(npix
`
)
dx
= lim
t→0+
`
2
+∞∑
n=1
an(t)bn .
We show now that
∑+∞
n=1 an(t)bn is a continuous function for t ≥ 0. We have
|an(t)bn| ≤ const
(
n
n2 + α′
1
n2 − β′ +
n3 + n
(αˆ+ n2)2
)
|bn|
for t ≥ 0 and n ≥ n0. Consequently
m∑
n=n0
|an(t)bn| ≤ const
m∑
n=n0
(
n
n2 + α′
1
n2 − β′ +
n3
(αˆ+ n2)2
)
|bn|
≤ const
(
m∑
n=n0
n2
(n2 + α′)2(n2 − β′)2 +
n6
(αˆ+ n2)4
) 1
2
(
m∑
n=n0
|bn|2
) 1
2
.
As
∑m
n=n0
n2
(n2+α)2(n2−β)2 and
∑m
n=n0
n3
(α+n2)4
are convergent sequences because the
corresponding series are convergent, and
∑m
n=n0
|bn|2 is convergent because Ψ ∈
L2(0, `), then
∑+∞
n=1 |an(t)bn| is convergent for t ≥ 0, and consequently
∑+∞
n=1 an(t)bn
is a continuous function for t ≥ 0.
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Using the previous property, we have
lim
t→0+
(g(t),Ψ) =
`
2
+∞∑
n=1
an(0)bn
= (g(0),Ψ) .
2.4. Qualitative behavior
In Theorem 2 we have presented an explicit expression for the drug concentration c
using a Fourier series. Considering a finite number of terms of such series, we obtain
an approximation for c. Here we shall consider N = 2000, that is
c2000(x, t) =
`− x
`
cext + e
αx+βt
2000∑
n=1
an(t) sin
(npix
`
)
.
In what follows we illustrate the behavior of c2000 for different values of the
parameters of the model. We start by illustrating the effect of the convection term,
induced by the electric field. We have taken cext = 1 (g/m2), D = 10−11 (m2/s),
` = 1.13× 10−3 m and z = −1. On figure 2.4 we present c2000(t) for different values
of t and with v = 0, a diffusion process. In figure 2.5 we present the concentration
c2000 when electromigration is present, with Φ0 = −0.02 V and Φ1 = 0.02 V. We
observe an increase in concentration levels in the last case, when compared to only
diffusion illustrated in figure 2.4.
Figure 2.4: Evolution of the concentration between 3 hours with just diffusion.
In figure 2.6 we illustrate the effect of the electric potential. In this figure we
plot the drug concentration c2000, using the same value for D = 10−11, with different
12
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Figure 2.5: Evolution of the concentration between 3 hours with electromigration.
`∇Φ = 0.02, 0.04 and 0.08, after the same time t = 3 h. We observe that as `∇Φ
increases, higher values of concentration are obtained.
Figure 2.6: Concentration after 3 hours with different potentials.
The effect of the diffusion coefficient in the transport process is illustrated in
figure 2.7, where we use for the same Φ0 = −0.02 and Φ1 = 0.02, different values of
D = 10−11, 2× 10−12 and 5× 10−11.
As we can see, small increases in the potential and the diffusion coefficient lead
to a general increase of the concentration after some time, whereas small decreases
lead to a decrease of the concentration.
We will now turn our attention towards the stationary solution of the problem.
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Figure 2.7: Concentration after 3 hours with different diffusion coefficients.
Solving ∂c∂t = 0 we obtain
c(x) =
cext
1− e v∗`D
(
e
v
D
x − e v∗`D
)
, x ∈ [0, `] .
Note that, from the expression for v in (2.8), the electric potential can influence
the stationary solution. In fact, we can see that a higher electrical potential leads to
higher stationary concentration levels. Furthermore, observing the expression for v
we can say that the diffusion coefficient does not influence the stationary state. In
figures 2.8 and 2.9 we plot the stationary solutions for `∇Φ = 0 and `∇Φ = 0.04
respectively.
Figure 2.8: Stationary state of concentration with `∇Φ = 0.
14
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Figure 2.9: Stationary state of concentration with `∇Φ = 0.04.
15
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Chapter 3
Drug in a polymeric reservoir
3.1. Introduction
In this Chapter we assume that the drug is contained in a polymeric reservoir which
is in contact with the target tissue. The electric field is generated applying the
cathode (anode) in the reservoir and the anode (cathode) in the oposite site, in
the target tissue depending on the electric charge of the drug as it was observed
in Chapter 2. Since we assume isotropic media, the 3D physical model can be
replaced by a 1D physical model as the one illustrated in figure 3.1. As the drug
transport in the reservoir and in the target tissue is enhanced by the electric field,
the drug mass flux Ji, i = r, s, has two main contributions, which are induced by
the Fickian transport and electromigration as in Chapter 2. We assume that the
two media have different diffusion and electrical conductivity coefficients. These
assumptions lead to two different Laplace equations for the electric potential that
are coupled by transference conditions at the contact boundary. The evolution of
the drug concentration is described by two convection-diffusion equations that are
coupled by transference conditions at the contact boundary.
The main objective of this Chapter is the study of the drug concentrations in dif-
ferent scenarios and it is organized as follows. In Section 3.2 we establish the coupled
model for the drug concentration. The stability analysis is presented in Section 3.3
using the energy method. The energy estimates are used in Section 3.4 to compute
lower bounds for the absorbed drug mass. A semi-analytical approach to solve the
drug coupled problem is presented in Section 3.5 which is a natural extension of the
one presented in Chapter 2. We remark that due to it's complexity, we do not use
such approach to solve the drug distribution. We introduce in Section 3.6 an explicit
numerical method for the coupled convection-diffusion equations. The stability of
the methods and its convergence are established under convergence assumptions on
the time and space step sizes. Numerical results illustrating the drug distribution in
different scenarios are included in Section 3.7.
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Anode/
Cathode
Cathode/
AnodeReservoir Tissue
x = 0 x = `1 x = `2
Figure 3.1: Considered coupled model.
3.2. The coupled drug distribution model
As illustrated in figure 3.1 we consider [0, `1] to be the reservoir and [`1, `2] the target
tissue, with x = `1 the contact point, and denote cr(x, t) the drug concentration in
x ∈ [0, `1] and cs(x, t) the drug concentration in x ∈ [`1, `2] at time t ≥ 0. We
assume that the left-hand side of the reservoir is isolated and the drug molecules
that reach the boundary x = `2 are immediately removed. In the domains (0, `1)
and (`1, `2) a diffusion process takes place enhanced by the electric field generated
by the applied electric potential Φ at x = 0 and x = `2, respectively, Φ0 and Φ1. We
assume that the polymeric matrix of the reservoir and the target tissue have different
electric conductivities σr and σs (S/m), respectively, as well as the drug has different
diffusion coefficients in both media, Dr and Ds, respectively.
The electric field in each medium is given by Ei = σi∇Φi, i = r, s and, neglecting
the electroosmosis transport, the drug mass flux in the reservoir Jr and in the target
tissue Js are given by
Ji = −Di∇ci − vici, i = r, s , (3.1)
where ci denotes the drug concentration in the medium i = r, s and vi is given by
vi =
zDiF
RTi
∇Φi, i = r, s , (3.2)
where z denotes the valence of the drug molecules, F the Faraday constant, Ti the
temperature in the medium i = r, s, and R the gas constant.
Solving the electric potential from the Laplace equation, with boundary condi-
tions Φr(0) = Φ0 and Φs(`2) = Φ1 and assuming at x = `1 the continuity of the
potentials and continuity of the electric field, the electric potentials Φi, i = r, s, are
described by the systems 
∇ · (σr∇Φr) = 0 in (0, `1)
Φr(0) = Φ0
(3.3)
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and 
∇ · (σs∇Φs) = 0 in (`1, `2)
Φs(`2) = Φ1
, (3.4)
coupled with the transition conditions
Φr(`1) = Φs(`1) (continuity of the potential)
σr∇Φr(`1) = σs∇Φs(`1) (continuity of the electric field)
. (3.5)
We remark that the first condition of (3.5) can be seen on as the limit of the Robin
type condition
Jr(`1) = α(Φr(`1)− Φs(`1)) (3.6)
when α→ +∞.
The mass conservation law on each medium
∂ci
∂t
+∇ · Ji = 0, i = r, s, (3.7)
together with (3.1) give us the convection-diffusion equations, for ci, i = r, s,
∂cr
∂t
= ∇ · (Dr∇cr) +∇ · (vrcr) in (0, `1)× R+
Dr∇cr(0, t) + vrcr(0, t) = 0, t ∈ R+0
(3.8)
and 
∂cs
∂t
= ∇ · (Ds∇cs) +∇ · (vscs) in ∈ (`1, `2)× R+
cs(`2, t) = 0, t ∈ R+0
. (3.9)
System (3.8), (3.9) is complemented with the following interface conditions
γcr(`1, t) = cs(`1, t) (continuity of the concentration)
Jr(`1, t) = Js(`1, t) (continuity of the mass flux)
, (3.10)
with γ ∈ [0, 1], and initial condition
cr(x, 0) = cr,0, x ∈ (0, `1)
cs(x, 0) = 0, x ∈ (`1, `2)
. (3.11)
Conditions (3.11) mean that the reservoir is initially with a homogeneous drug
distribution and that the target tissue is empty.
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Solving the potential problems (3.3), (3.4) and (3.5) we obtain
Φr(x) =
Φ1 − Φ0
`1 +
σr
σs
(`2 − `1)x+ Φ0, x ∈ [0, `1)
Φs(x) =
σr
σs
Φ1 − Φ0
`1 +
σr
σs
(`2 − `1)
(
x− `2
)
+ Φ1, x ∈ [`1, `2]
. (3.12)
From (3.12) and (3.2) we deduce the convective velocities
vr =
DrzF
RTr
Φ1 − Φ0
`1 +
σr
σs
(`2 − `1)
vs =
DszF
RTs
σr
σs
Φ1 − Φ0
`1 +
σr
σs
(`2 − `1)
. (3.13)
Finally the drug distribution in he reservoir r and in the target tissue s is described
by (3.8)-(3.11) with the convective velocities given by (3.13).
3.3. Stability analysis
To study the stability of the coupled IBVP (3.8)-(3.11), (3.13) we introduce the space
V = {w ∈ H1(0, `2) : w(`2) = 0}. Let D and v be defined by
D =

Dr, x ∈ (0, `1)
Ds, x ∈ (`1, `2)
, v =

vr, x ∈ (0, `1)
vs, x ∈ (`1, `2)
.
Then we replace the coupled IBVP for the drug evolution by the following initial
value problem: find, for each t ∈ R+, c(t) ∈ V such that c′(t) ∈ L2(0, `2) and
(c′(t), w) = −(D∇c(t),∇w)− (vc(t),∇w), t ∈ R+, ∀w ∈ V, (3.14)
where (., .) denotes the usual inner product in L2(0, `2), and
c(0) = cr,0 in [0, `1], c(0) = 0 in (`1, `2]. (3.15)
The drug distribution is then defined by
cr(t) = c(t) in [0, `1], cs(t) = c(t) in [`1, `2].
To study the stability of the weak problem (3.14)-(3.15) we recall that the fol-
lowing Friedrich-Poincaré inequality
‖w‖2 ≤ `
2
2
2
‖∇w‖2, w ∈ V, (3.16)
holds. In the next results we establish energy estimates for c(t) :
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Theorem 3. If c(t) ∈ V is a solution of (3.14), (3.15) then
‖c(t)‖2 ≤ e
(
− 2
`22
mini=r,sDi+maxi=r,s
v2i
Di
)
t‖c(0)‖2, t ∈ R+0 . (3.17)
Proof. Taking in (3.14) w = c(t) we have
d
dt
‖c(t)‖2 = −2‖
√
D∇c(t)‖2 − 2(vc(t),∇c(t)). (3.18)
As
2(vc(t),∇c(t)) ≤
∑
i=r,s
(
v2i
1
2ε2i
‖c(t)‖2i + 2ε2i ‖∇c(t)‖2i
)
,
with εi 6= 0, where ‖.‖i, for i = r, s, denotes the L2 norm in the reservoir and in the
target tissue, respectively, we deduce
d
dt
‖c(t)‖2 ≤
∑
i=r,s
((− 2Di + 2ε2i )‖∇c(t)‖2i + v2i 12ε2i ‖c(t)‖2i
)
.
If we fix now ε2i =
1
2
Di, then we establish
d
dt
‖c(t)‖2 ≤
∑
i=r,s
(
−Di‖∇c(t)‖2i +
v2i
Di
‖c(t)‖2i
)
,
that implies
d
dt
‖c(t)‖2 ≤ −min
i=r,s
Di‖∇c(t)‖2 + max
i=r,s
v2i
Di
‖c(t)‖2.
Applying the inequality (3.16) we obtain
d
dt
‖c(t)‖2 ≤
(
− 2
`22
min
i=r,s
Di + max
i=r,s
v2i
Di
)
‖c(t)‖2
that leads to (3.17).
From Theorem 3 we conclude the stability of the IBVP (3.14), (3.15) for bounded
time intervals and if c(t), c˜(t) ∈ V are solutions of this problem then c(t) = c˜(t).
3.4. An estimate for the absorbed mass
The upper bound (3.17) can be used to study the qualitative behavior of the drug
mass inside of the coupled system and the absorbed drug. Let
M(t) =
∫ `2
0
c(x, t) dx, t ∈ R+0 ,
be the drug mass in the coupled system. As
M(t) ≤
√
`2‖c(t)‖,
from Theorem 3 we obtain an upper bound for such mass.
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Corollary 1. Under the assumptions of Theorem 3, we have
M(t) ≤
√
`2e
1
2
(− 2
`22
mini=r,sDi+maxi=r,s
v2i
Di
)t‖c(0)‖, t ∈ R+0 . (3.19)
Moreover, if
maxi=r,s
v2i
Di
Di
<
2
`22
, i = r, s, (3.20)
then
lim
t→∞M(t) = 0 exponentially. (3.21)
Let Mabs(t) be the absorbed mass. We have
Mabs(t) = M(0)−M(t), t ∈ R+0 .
and consequently
Mabs(t) ≥M(0)−
√
`2e
1
2
(− 2
`22
mini=r,sDi+maxi=r,s
v2i
Di
)t‖c(0)‖, t ∈ R+0 . (3.22)
We remark that condition (3.20) can be a reasonable assumption at least for thin
reservoirs where `1 is small.
To obtain a second estimate for M(t), we need to improve the estimate (3.17).
From (3.18) we deduce
d
dt
‖c(t)‖2 ≤ −2 min
i=r,s
Di‖∇c(t)‖2 + 2`2 max
i=r,s
|vi|‖c(t)‖‖∇c(t)‖,
that leads to
d
dt
‖c(t)‖2 ≤
(
− 2 min
i=r,s
Di +
√
2`2 max
i=r,s
|vi|
)
‖∇c(t)‖2.
Assuming that
|vi|
Di
<
2
√
2
`2
, i = r, s, (3.23)
we obtain
d
dt
‖c(t)‖2 ≤
(
− 2 min
i=r,s
Di +
√
2`2 max
i=r,s
|vi|
) 2
`22
‖c(t)‖2,
and finally
‖c(t)‖2 ≤ e
2
`22
(−2 mini=r,sDi+
√
2`2 maxi=r,s |vi|)t‖c(0)‖2, t ∈ R+0 . (3.24)
From the previous considerations we conclude that under the condition (3.23),
we have
M(t) ≤
√
`2e
1
`22
(−2 mini=r,sDi+
√
2`2 maxi=r,s |vi|)t‖c(0)‖, t ∈ R+0 , (3.25)
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and
Mabs(t) ≥M(0)−
√
`2e
1
`22
(−2 mini=r,sDi+
√
2`2 maxi=r,s |vi|)t‖c(0)‖, t ∈ R+0 . (3.26)
The condition (3.23) is less restrictive than the condition (3.20) and the upper bound
of (3.19) for the drug mass in the reservoir-target tissue is grater than the upper
bound in (3.25). To conclude this Section we finally observe that the estimates
(3.22) and (3.26) allow the evaluation of lower bounds for the absorbed massMabs(t)
provided that such lower bounds are positive.
In figure 3.2 we plot the absorbed mass computed numerically using the numerical
method that will be studied in Section 3.6 and the lower bounds (3.22) and (3.26) for
`1 = 10
−3, `2 = 1.2× 10−3, Tr = Ts = 310.15, σr = 1.5× 10−5, σs = 10−7, cr,0 = 1,
Dr = 0.65× 10−10, Ds = 1× 10−10, Φ0 = −0.0001, Φ1 = 0.0001 and z = −1 in a 6
hour iontophoresis procedure.
We observe that, from lower bound (3.22), after 6h the absorbed mass is greater
that 0.8mg and after 4h it is already at least 0.6mg, while from (3.26) we conclude
that after 6h it is greater than 0.5mg, being the absorbed mass approximately 0.9mg.
Figure 3.2: Absorbed mass at x = `2 with the obtained lower bounds.
3.5. A semi-analytical Fourier method
In what follows we use the method of separation of variables to construct a solu-
tion for the coupled IBVP (3.8)-(3.11), (3.13). We remark that in [18] the same
methodology was used for a coupled problem.
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Assuming that ci(x, t) = Mi(x)Ni(t), for i = r, s, we obtain
M ′′i +
vi
Di
M ′i = λiMi, N
′
i = DiλiNi, i = r, s . (3.27)
Considering the new variables x˜ =
x− `1
`1
and M˜i(x) = e
− vi
2Di
x
Mi(x), for i = r, s,
we can write the following spatial eigenvalue problems
M˜ ′′r = λ˜rM˜r, x˜ ∈ (−1, 0), M˜ ′′s = λ˜sM˜s, x˜ ∈ (0, ˜`) (3.28)
with λ˜i =
v2i
4Di
+ λi, for i = r, s, that are coupled with the following conditions
DrM˜
′
r(−1) + 3vr2 M˜r(−1) = 0
γM˜r(0) = M˜s
DrM˜
′
r(0) +
3vr
2 M˜r(0) = DsM˜
′
s(0) +
3vs
2 M˜s(0)
M˜s(˜`) = 0
. (3.29)
To obtain the desired Fourier series we need to solve (3.28) and (3.29). Let
us suppose that λ˜i < 0, otherwise we obtain an exponential representation of M˜i,
i = r, s. Replacing λ˜i by −λ˜2i , i = r, s, in (3.28) we obtain the eigenfunctions
M˜i(x˜) = ai cos(λ˜ix˜) + bi sin(λ˜ix˜), i = r, s . (3.30)
From conditions (3.29) we can write the linear system for ar, br, as and bs
Drkr sin(λ˜r) +
3vr
2
cos(λ˜r) Drλ˜r cos(λ˜r) +
3vr
2
sin(λ˜r) 0 0
γ 0 −1 0
3vr
2
−Drλ˜r − 3vs2 Dsλ˜s
0 0 cos(λ˜s ˜`) sin(λ˜s ˜`)


ar
br
as
bs
 =

0
0
0
0

(3.31)
System (3.31) admits the following solution
as = γar
br =
3vr
2
(1−γ)+Dsλ˜scotg(λ˜s ˜`)
Drλ˜r
ar
bs = −γcotg(λ˜s ˜`)ar
(3.32)
for as ∈ R if and only if the matrix of this system is singular, that is,(
Drλ˜r cos(λ˜r) +
3vr
2
sin(λ˜r)
)(
γDsλ˜s cos(λ˜s ˜`) + sin(λ˜s ˜`)
3(γvs − vr)
2
)
+(
Drkr sin(λ˜r) +
3vr
2
cos(λ˜r)
)
(−Drλ˜r sin(λ˜s ˜`)) = 0 (3.33)
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As we have
Ni(t) = e
DiλitNi(0), i = r, s ,
we obtain
ci(x, t) = e
DiλitNi(0)Mi(x), i = r, s .
The first interface condition at x = `1 holds if and only if
γeDrλrtNr(0)Mr(0) = e
DsλstNs(0)Ms(0) .
As γM˜r(0) = M˜s(0) we conclude that
M˜s(0)
[
eDrλrtNr(0)− eDsλstNs(0)
]
= 0
which implies M˜s(0) = 0 or eDrλrtNr(0) = eDsλstNs(0). Since M˜s(0) = 0 leads to
the null solutions M˜i, i = r, s, we set
eDrλrtNr(0) = e
DsλstNs(0)
for any initial condition. This implies in particular that
Drλr = Dsλs . (3.34)
Equations (3.33) and (3.34) should lead to a set of eigenvalues λi, i = r, s, and
then using (3.32), the corresponding eigenfunctions M˜i, i = r, s are obtained. Finally
using Ni, i = r, s, we obtain ci, i = r, s.
The procedure described before, requires the use of a numerical method to solve
equations (3.33) and (3.34) because we are not able to obtain explicit expressions
for λr and λs. Then, using the corresponding values, we get the corresponding
eigenfunctions.
The complexity of the presented Fourier method is a motivation for the next
section, where we present a numerical method to solve the IBVP (3.8) - (3.10).
3.6. A discrete approach
3.6.1. An explicit Euler method
Let T > 0 be fixed and Q = [0, `2] × [0, T ]. Given N ≥ 4 and M ≥ 1 integers, let
h = `2/N and ∆t = T/M , we define the non-uniform mesh Q∆th on Q by
Q∆th = {(xi, tm) : x1 = 0; xN = `2; xi+1−xi = hi, 0 ≤ i ≤ N ; tm = m∆t, 0 ≤ m ≤M}
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x0
x1
x2
x3 x4 . . .
xN1−1
xN1
xN1+1
. . . xN
h
Figure 3.3: Spatial grid.
where x0 is an auxiliary point, xN1 is the transition point and hi is given by
xi+1 − xi = hi =

h
2 , i ∈ {0, 1, N1, N1 + 1}
h, i ∈ {2, ..., N1 − 1, N1 + 2, ..., N}
. (3.35)
The spatial grid is illustrated in figure 3.3.
By D+x , D
−
x we denote the usual forward and backward finite difference operators
on space respectively. The first and second order centered finite difference operators
are denoted by Dcx and D
2
x, respectively. Finally we introduce the notation for the
backward finite difference operator in time D−t . By Umi,l we represent the approxi-
mation of the solution for ci(xl, tm), for i = r, s defined by
D−t Umr,i = DrD
2
xU
m
r,i +D
c
xvrU
m
r,i , i ∈ {1, ..., N1 − 1}
U0r,i = cr,0 , i ∈ {1, ..., N1 − 1}
DrD
c
xU
m
r,1 +
vr(Umr,0+2U
m
r,1+U
m
r,2)
4 = 0 , m ≥ 0 ,
(3.36)

D−t Ums,i = DrD
2
xU
m
s,i +D
c
xvsU
m
s,i , i ∈ {N1 + 1, ..., N − 1}
U0s,i = 0 , i ∈ {N1 + 1, ..., N − 1}
Ums,N = 0 , m ≥ 0 ,
(3.37)
with the transition conditions
DrD
−
x U
m
r,N1
+ vr
Umr,N1−1+U
m
r,N1
2 = DsD
+
x U
m
s,N1
+ vs
Ums,N1
+Ums,N1+1
2 , m ≥ 0
γUmr,N1 = U
m
s,N1
, m ≥ 0 .
(3.38)
To obtain a matrix representation of the finite differene method, we start by
solving the last equation of (3.36) for Umr,0. We obtain
Umr,0 =
2vrh
4Dr − vrhU
m
r,1 +
4Dr + vrh
4Dr − vrhU
m
r,2
and considering now this expression in the first equation of (3.36) for i = 1 we deduce
Umr,1 =
(
1− 8Dr∆t
h2
+ 2Dr
∆t
h
)
Um−1r,1 + 2
∆t
h2
(4Dr + vrh)U
m−1
r,2 .
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Taking i = 2 in the first equation of (3.36) we get
Umr,2 =
2
3
∆t
h2
(4Dr − vrh)Um−1r,1 +
(
1− 4∆t
h2
Dr
)
Um−1r,2
+
2
3
∆t
h2
(Dr + vrh)U
m−1
r,3 .
For i ∈ {3, ..., N1 − 2} we have
Umr,i =
∆t
h2
(Dr − vrh))Um−1r,i−1 +
(
1− 2∆t
h2
Dr
)
Um−1r,i
+
∆t
h2
(Dr + vrh))U
m−1
r,i+1 .
From the system (3.38) we obtain
Umr,N1 =
(
4Dr − vrh
4(γDs +Dr) + (vr − γvs)h
)
Umr,N1−1
−
(
4Ds + vsh
4(γDs +Dr) + (vr − γvs)h
)
Ums,N1+1 .
Considering this result in the first equation of (3.36) for i = N1 − 1 and in the first
equation of (3.37) for i = N1 + 1 we establish
Umr,N1−1 =
2
3
∆t
h2
(2Dr − vrh)Um−1N1−2
+
(
1− 4∆t
h2
Dr +
2
3
∆t
h2
(2Dr + vrh)(4Ds − vsh)
4(Dr + γDs) + h(vr − γvs)
)
Um−1r,N1−1
+
2
3
∆t
h2
(
(2Dr + vrh)(4Ds + vsh)
4(Dr + γDs) + h(vr − γvs)
)
Um−1s,N1+1
and
Ums,N1+1 =
2
3
∆t
h2
(
(2Ds − vsh)(4Dr − vrh)
4(Dr + γDs) + h(vr − γvs)
)
Um−1r,N1−1
+
(
1 + 4
∆t
h2
Ds +
2
3
∆t
h2
(2Ds − vsh)(4Ds + vsh)
4(Dr + γDs) + h(vr − γvs)
)
Um−1s,N1+1
+
2
3
∆t
h2
(2Ds + vsh)U
m−1
s,N1+2
.
Finally when i ∈ {N1 + 2, ..., N − 1} we have
Ums,i =
∆t
h2
(Ds − vsh)Um−1s,i−1 +
(
1− 2∆t
h2
Ds
)
Um−1s,i
+
∆t
h2
(Ds + vsh)U
m−1
s,i+1 ,
respectively.
The previous system can be rewritten in the following equivalent form
Um+1 = Ah,∆tU
m, m = 1, . . . ,M , (3.39)
where Umi = U
m
r,i, for i ∈ {1, . . . , N1 − 1}, Umi = Ums,i, for i ∈ {N1 + 1, . . . , N} and
U0 is known.
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3.6.2. Stability
From (3.39) we obtain
∥∥Um+1∥∥∞ ≤ ‖Ah,∆t‖m∞ ∥∥U0∥∥∞ .
Then
‖Um‖∞ ≤
∥∥U0∥∥∞ (3.40)
provided that ‖Ah,∆t‖∞ ≤ 1. Inequality (3.40) means that that the operator Ah,∆t
is stable.
In what follows we take γ = 1. Recalling the observations from figures 2.2 and
2.3, and taking into account that vi is given by (3.13), we have vi < 0, for i = r, s.
We shall impose a set of conditions on the time and space step sizes that lead to
‖Ah,∆t‖∞ ≤ 1.
Let A1 be the first line of Ah,∆t. We have
‖A1‖1 = 2
∆t
h2
|4Dr + vrh|+ |1− 2∆t
h2
(Dr − vrh)| .
If
h <
4Dr
−vr (3.41)
and
2
∆t
h2
(4Dr − vrh) < 1 (3.42)
we get ‖A1‖1 = 1.
For the second line of Ah,∆t we deduce
‖A2‖1 = 2
∆t
h2
(4Dr − vrh) +
∣∣∣∣1− 4∆th2 Dr
∣∣∣∣+ 23 ∆th2 |2Dr + vrh| .
If
h <
2Dr
−vr (3.43)
and
∆t
h2
<
1
4Dr
(3.44)
we can conclude ‖A2‖1 = 1. We remark that (3.43) implies (3.41), while (3.42) and
(3.43) implies (3.44).
For the lines Ai, i ∈ {3, . . . , N1 − 1} of matrix Ah,∆t we have
‖Ai‖1 = 2
∆t
h2
(Dr − hvr
2
) +
∣∣∣∣1− 2∆th2 Dr
∣∣∣∣+ ∆th2 |Dr + vrh|
and conditions (3.44), (3.43) allow us to write ‖Ai‖1 = 1.
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For the line AN1−1 we deduce
‖AN1−1‖1 =
2
3
∆t
h2
(2Dr − vrh)
+
∣∣∣∣1− 4∆th2 Dr + 23 ∆th2 (2Dr + vrh)(4Dr − vrh)4(Dr +Ds) + h(vr − vs)
∣∣∣∣
+
2
3
∆t
h2
∣∣∣∣ (2Dr + vrh)(4Ds + vsh)4(Dr +Ds) + h(vr − vs)
∣∣∣∣ .
If vs − vr > 0 then for h < 4(Dr+Ds)vs−vr , h < 2 Dr−vr , ∆th2 < 14Dr and h < 4Ds−vs we obtain
‖AN1−1‖1 =
2
3
∆t
h2
(2Dr − vrh) + 1− 4∆t
h2
Dr +
2
3
∆t
h2
(2Dr + vrh)
4(Dr +Ds)− h(vr − vs)
4(Dr +Ds) + h(vr − vs)
≤ 1− 4∆t
h2
Dr +
8
3
∆t
h2
Dr
≤ 1 .
The line AN1 satisfies
‖AN1‖1 =
2
3
∆t
h2
(2Ds − vsh)(4Dr − vrh)
4(Dr +Ds) + h(vr − vs)
+
∣∣∣∣1− 4∆th2 Ds + 23 ∆th2 (2Ds − vsh)(4Ds + vsh)4(Dr +Ds) + h(vr − vs)
∣∣∣∣
+
∣∣∣∣23 ∆th2 (2Ds + vsh)
∣∣∣∣ .
Since vi < 0 for i = r, s, h < 2Ds−vs , h <
4(Dr+Ds)
vs−vr ,
∆t
h2
< 14Ds , we obtain ‖AN1‖1 ≤ 1.
For i ∈ {N1 + 1, . . . , N − 1}, the lines Ai−1 satisfy
‖Ai−1‖1 =
∆t
h2
|(Ds − vsh)|+
∣∣∣∣1− 2∆th2 Ds
∣∣∣∣+ ∆th2 (Ds + vsh) .
Assuming h < Ds−vs ,
∆t
h2
< 12Ds we get ‖Ai−1‖1 = 1, for i ∈ {N1 + 1, . . . , N − 1}.
The following proposition summarizes the previous conclusions:
Proposition 1. If γ = 1, vs − vr > 0, where vr and vs are defined by (3.13) and
h < 2 min
i=r,s
Di
−vi , (3.43)
∆t
h2
< min
i=1,2
1
4Di
, (3.44) h ≤ 4(Dr +Ds)
vr − vs , (3.45)
then the finite difference scheme (3.39) is stable. If vs − vr < 0 then the scheme is
stable under the assumptions (3.43) and (3.44).
In figure 3.4 we plot the drug concentration obtained with parameters which
violate condition (3.44). We used `1 = 10−3, `2 = 1.2 × 10−3, Tr = Ts = 37oC,
Dr = 10
−11, Ds = 10−12, σr = 1.5 × 10−5, σs = 10−7, c(x, 0) = 1, x ∈ (0, `1),
c(x, 0) = 0, x ∈ (`1, `2), z = −1, Φ0 = −0.5, and Φ1 = 1. The discretization
parameters where N = 65,M = 10000 which leads to h ≈ 1.85×10−5 and ∆t = 2.16.
We remark the instability that is observed near the point x = `2.
29
Chapter 3 Drug in a polymeric reservoir
Figure 3.4: Representation of the instability.
3.6.3. Convergence
The convergence analysis is based on the stability Proposition 1 and in the consis-
tency of the method (3.39). By Th,∆t we represent the truncation error induced by
(3.39). Let elh,∆t(xi, tm), l = r, s be the error of the numerical approximation U
m
i ,
for i = 1, . . . , N1 − 1, N1, N1 + 1, . . . , N . The errors eh,∆t and Th,∆t satisfy
• DrDcxerh,∆t(x1, tm) + vr
erh,∆t(x0, tm) + 2e
r
h,∆t(x1, tm) + e
r
h,∆t(x2, tm)
4
= Th,∆t(x1, tm) ,
• D−t erh,∆t(xi, tm) = DrD2xerh,∆t(xi, tm) +Dcx(vrerh,∆t(xi, tm))
+ Th,∆t(xi, tm), i = 2, 3, . . . , N1 − 1 ,
• γerh,∆t(xN1 , tm) = esh,∆t(xN1 , tm) ,
• DrD−x erh,∆t(xN1−1, tm) + vr
erh,∆t(xN1 , tm) + e
r
h,∆t(xN1 , tm)
2
= DsD
+
x e
s
h,∆t(xN1 , tm) + vs
esh,∆t(xN1 , tm) + e
s
h,∆t(xN1+1, tm)
2
+ Th,∆t(xN1−1, tm) ,
• D−t esh,∆t(xi, tm) = DsD2xesh,∆t(xi, tm) +Dcx(vsesh,∆t(xi, tm))
+ Th,∆t(xi, tm), i = N1 + 1, . . . , N − 1 .
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It is easy to show that
D−t cl(xi, tm) =
∂cl
∂t
(xi, tm) +O(∆t) , (3.46)
D+x cl(xi, tm) =
∂cl
∂x
(xi, tm) +O(hi+1) , (3.47)
D−x cl(xi, tm) =
∂cl
∂x
(xi, tm) +O(hi) , (3.48)
Dcxcl(xi, tm) =
∂cl
∂x
(xi, tm) +O
(
hi+1 − hi
2
+
h3i+1 + h
3
i
6(hi+1 + hi)
)
=
∂cl
∂x
(xi, tm) +

O (h2) , hi = hi+1
O (h) , hi 6= hi+1
, (3.49)
D2xcl(xi, tm) =
∂2cl
∂x2
(xi, tm) +O
(
hi+1 − hi
3
+
hih
4
i+1 + hi+1h
4
i
12(hi + hi+1)
)
=
∂2cl
∂x2
(xi, tm) +

O (h2) , hi = hi+1
O (h) , hi 6= hi+1
, (3.50)
for i ∈ {1, . . . , N1 − 1} if l = r and i ∈ {N1 + 1, . . . , N − 1} if l = s, with m ∈
{1, . . . ,M}. From the previous considerations, it is easy to conclude
Th,∆t(xi, tm) =

O (h+ ∆t) , i ∈ {2, N1 − 1, N1 + 1}, m ∈ {1, . . . ,M}
O (h2 + ∆t) , i /∈ {2, N1 − 1, N1 + 1}, m ∈ {1, . . . ,M} (3.51)
which leads to |Th,∆t(xi, tm)| = O(h+ ∆t), for i = 1, 2, . . . , N − 1.
Let eh,∆t(tm) be defined as Um. Then it can be shown that
eh,∆t(tm) = Ah,∆t eh,∆t(tm−1) + ∆t T˜h,∆t(tm) , (3.52)
where T˜h,∆t(tm) depends on Th,∆t(tm) and satisfies
∥∥∥T˜h,∆t(tm)∥∥∥∞ = O (h+ ∆t).
From (3.52) we obtain
‖eh,∆t(tm)‖∞ ≤ ‖Ah,∆t‖∞ ‖eh,∆t(tm−1)‖∞ + ∆t
∥∥∥T˜h,∆t(tm)∥∥∥∞ .
Under the assumptions of Proposition 1, we deduce
‖eh,∆t(tm)‖∞ ≤ ‖eh,∆t(tm−1)‖∞ + ∆t
∥∥∥T˜h,∆t(tm)∥∥∥∞
and it follows that
‖eh,∆t(tm)‖∞ ≤ T max1≤j≤M
∥∥∥T˜h,∆t(tj)∥∥∥∞ (3.53)
because ‖eh,∆t(t0)‖∞ = 0. Inequality (3.53) means that the proposed method is
convergent.
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In what follows we illustrate the convergence of the method under the assump-
tions stated in Proposition 1.
An illustration of the spatial order of convergence and associated error in norm
‖·‖∞ is given in comparison with a solution obtained with very small h = 4.6 ×
10−6 and ∆t = 0.165. In figures 3.5 we plot the reference solution and numerical
approximations obtained with `1 = 10−3, `2 = 1.2 × 10−3, Tr = Ts = 37oC, Dr =
10−11, Ds = 10−12, σr = 1.5 × 10−5, σs = 10−7, c(x, 0) = 1, x ∈ (0, `1), c(x, 0) =
0, x ∈ (`1, `2), z = −1, Φ0 = −0.05, Φ1 = 0.05 and T = 6h. As it can be seen, an
increase of the number of spatial points leads to a decrease of the associated error.
Figure 3.5: Error of the approximation.
In figure 3.6 we plot the errors ‖eh,∆t(T )‖∞.
Figure 3.6: Spatial error.
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3.7. Numerical Results
The objective of this Section is the illustration of the behavior of the drug concen-
tration for the parameters previously used in the convergence experiments.
In figure 3.7 we plot the drug concentration when vi = 0, i = r, s, this means
that the transport phenomena occur only by diffusion. As time evolves, the value
of the drug concentration decreases, mainly in the reservoir. To illustrate the effect
of the electric field, we plot in figure 3.8 the numerical results obtained considering
Φ0 = −0.05 and Φ1 = 0.05. From figures 3.7 and 3.8 we conclude that the drug
release from the reservoir as well as the entrance in the target tissue and absorption
in x = `2 is enhanced by the applied potential. The drug concentrations obtained
with Φ0 = −0.5, Φ1 = 1 are plotted in figure 3.9. From the figures 3.7 - 3.9 we can
infer that an increase of the strength of the electric field is followed by a decrease of
the drug concentrations.
The absorbed mass drug at x = `2, M(t), is presented in figure 3.10 for vr =
vs = 0. The corresponding absorbed mass when an electric potential is applied, for
Φ0 = −0.05, Φ1 = 0.05 and Φ0 = −0.5, Φ1 = 1 are plotted in figures 3.11 and 3.12.
As before, we conclude that as the electric field increases, the drug delivery process
increases as well, and consequently, the absorbed mass. The same conclusions are
obtained from figures 3.13 - 3.15, where we plot the mass drug fluxes at x = `2.
Figure 3.7: Drug concentration in the coupled system with diffusion only.
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Figure 3.8: Drug concentration in the coupled system with Φ0 = −0.05, Φ1 = 0.05.
Figure 3.9: Drug concentration in the coupled system with Φ0 = −0.5, Φ1 = 1.
Figure 3.10: Absorbed mass at x = `2 with diffusion only.
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Figure 3.11: Absorbed mass at x = `2 with Φ0 = −0.05, Φ1 = 0.05.
Figure 3.12: Absorbed mass at x = `2 with Φ0 = −0.5, Φ1 = 1.
Figure 3.13: Drug flux at x = `2 with diffusion only.
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Figure 3.14: Drug flux at x = `2 with Φ0 = −0.05, Φ1 = 0.05.
Figure 3.15: Drug flux at x = `2 with Φ0 = −0.5, Φ1 = 1.
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Conclusions
In this work we studied the drug delivery of electric charged drugs from a polymeric
reservoir and its entrance in a target tissue. To enhance the diffusion transport in the
reservoir and in the target tissue, an applied potential is considered. This potential
induces a convective mass flux that increases the drug release.
To simplify our study, in Chapter 2 we assume that the drug is in contact with
the target tissue and that the drug release is described by a convection-diffusion
equation where the convective velocity is given by the Nernst-Planck equation. In
Chapter 3 we consider that the drug is contained in a reservoir which is in contact
with the target tissue. In this case, the drug transport and its absorption in by the
target tissue is described by two convection-diffusion equations that are coupled at
the contact boundary. In both chapters we consider isotropic media which lead to
1D mathematical models, and the absorption of the drug in the target tissue was
defined by a homogenous Drichlet boundary condition.
Two questions need to be object of study: the drug release of a polymeric reser-
voir when the drug absorption is described by a Robin boundary condition and when
an anisotropic media is considered. This last assumption leads to 2D and 3D math-
ematical models.
The drug release was studied during a continuous period of application of the
electric potential. In iontophoretic applications, the potential is applied during a
certain time period which is followed by a rest period. This means that the boundary
conditions defining the electric potentials are step functions. In the near future we
intend to extend the obtained results to these more realistic situations.
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